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ORIGINAL REPORT
Assessing the availability of the teratogenic drug isotretinoin outside
the pregnancy prevention programme: a survey of e-pharmacies†
Briege M. Lagan1, Helen Dolk1, Bronagh White1, Donald R. A. Uges2 and M. Sinclair1*
1University of Ulster, Northern Ireland, UK
2University Medical Center, Groningen, Netherlands
ABSTRACT
Purpose The increase in online purchasing of medications raises safety concerns regarding teratogenic drugs. The use of the teratogenic
drug ‘isotretinoin’ for women of childbearing age requires strict adherence to the Pregnancy Prevention Programme (PPP), a risk
minimisation measure imposed on prescribers and users. We sought to determine how readily consumers can purchase isotretinoin online
and the associated safety procedures and information.
Methods A descriptive cross-sectional survey was conducted of 50 e-pharmacies identiﬁed from commonly used search engines. E-pharmacy
characteristics and isotretinoin PPP speciﬁc criteria were evaluated. Purchases of isotretinoin from seven e-pharmacies not bearing authentication
logos and not requiring a prescription were assessed for PPP policy adherence, purchasing procedures and compound quality.
Results Forty-three (86%) of the e-pharmacies did not have an authentication seal/logo. Isotretinoin could be purchased from 42 sites with-
out a valid prescription. Information on isotretinoin causing birth defects was lacking in 25 of the 50 sites, on not taking isotretinoin in preg-
nancy in 24 sites and not taking isotretinoin if planning or at risk of a pregnancy in 33 sites. Of the eight attempted purchases, seven arrived,
all without any patient information leaﬂet. All were veriﬁed as isotretinoin.
Conclusion The Internet provides a loophole for purchasing of medications known to cause congenital abnormalities, which needs to be
addressed by medicines regulatory agencies worldwide. The current PPP for isotretinoin may be failing to protect mothers and babies from
preventable harm—clinicians need to be aware of this, and the public needs to be educated about the potential risks. © 2014 The Authors.
Pharmacoepidemiology and Drug Safety published by John Wiley & Sons, Ltd.
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INTRODUCTION
The increase in online purchasing of medication raises
numerous safety concerns,1 particularly for teratogenic
drugs—medications which if taken in early pregnancy
can cause birth defects. Isotretinoin (brand name
Accutane®/Roaccutane®) is a commonly used and
effective drug for the treatment of severe acne vulgaris
that has not responded to other treatments.2–4 However,
it is known to cause birth defects.5,6 Pregnancy is an
absolute contraindication to treatment with isotretinoin
as harm to the fetus may occur before the pregnancy is
known, and the teratogenic potential remains up to
1month following stoppage.2,3 There is a 25-fold rela-
tive risk for birth defects with a characteristic pattern of
craniofacial, cardiac, thymic and central nervous sys-
tem malformations among babies of women exposed
to isotretinoin in early pregnancy.6
The use of the drug for women of childbearing age
requires strict adherence to a Pregnancy Prevention
Programme (PPP), a risk minimisation measure imposed
on prescribers and users as a condition of licensing.2,3
PPPs were ﬁrst introduced in 1988 with the aim of
preventing isotretinoin-exposed pregnancies. Since then,
studies revealing poor compliance and higher than
acceptable pregnancy rates have led to progressively
stricter PPPs in the USA and in Europe with the pre-
scribing of isotretinoin limited to dermatologists and
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selected clinicians. A prerequisite of these programmes
is that women of childbearing age must sign up to ef-
fective contraception and regular pregnancy tests.2,3
Doubt continues to be expressed about the effectiveness
of PPPs,7 as a number of identiﬁed isotretinoin-exposed
pregnancies are still being reported.8,9 Non-compliance
among physicians and women has been highlighted as
a problem.10,11 Honein and colleagues reported over
10 years ago that women obtained isotretinoin from
sources other than registered prescribers.12
In the recent years, the online sales of pharmaceuti-
cals have become a rapidly growing phenomenon, and
sales continue to escalate.1,13 In 2004, the US Govern-
ment Accountability Ofﬁce recognised that consumers
could purchase isotretinoin online without a prescrip-
tion,14 and more recently, Lott and Kovarik reported
the proliferation of websites purporting to sell derma-
tologic medications without prescription, including
isotretinoin.15
In the context of a wider study to assess the implica-
tions of the Internet in relation to medication access and
safety information for pregnancy (http://euromedicat.eu/)
and in the light of the ongoing need to review the effec-
tiveness of the PPP for isotretinoin, this paper reports a
study to determine how readily consumers can purchase
isotretinoin online and the associated safety procedures
and information.
METHODS
The ﬁrst phase of the study involved a cross-sectional
descriptive survey identifying e-pharmacies (also com-
monly known as Internet or online pharmacies) acces-
sible from the UK (September 2011) purporting to
sell isotretinoin and evaluating each site in terms of
e-pharmacy characteristics and isotretinoin PPP speciﬁc
safety criteria. The second phase involved purchasing
isotretinoin from a randomly selected subset of the
e-pharmacies not bearing authentication logos, assessing
these sites for PPP policy adherence and purchasing pro-
cedures and analysing the samples to check for chemical
authenticity.
Search strategy
The term ‘buy isotretinoin’was entered into the ﬁve most
common search engines in order of ranking used by lay-
persons16—Google.com, Yahoo.com, Bing.com, Ask.
com and Teoma.com. Eligible sites were e-pharmacies
accessible in the UK claiming to sell isotretinoin.
Websites that were duplicate matches within a search
engine or identiﬁed from a previous search engine,
had a non-functional link, were purely an advertising
site, inaccessible or a portal for other sites or not in
English were excluded. As themajority of users tend only
to examine the ﬁrst 10 results they obtain from a search
engine,17 the ﬁrst 10 eligible non-excluded e-pharmacy
sites sequentially found within each of the search engines
were selected for evaluation. In total, 242 sites were
accessed by this process before the target sample of
10 different e-pharmacies (50 in total) from each search
engine was achieved.
Evaluation of e-pharmacy characteristics. A Web-
based IP address lookup location tool was used to trace
the geographical location of each e-pharmacy. For the
purposes of this study, an e-pharmacy was classiﬁed as
‘legitimate’ if it had an authentic accreditation seal/logo
(e.g. Veriﬁed Internet Pharmacy Practice Sites Programme
(VIPP),18 Canadian International Pharmacy Association19
or General Pharmaceutical Council20). Such seals/logos
assure consumers that the pharmacy provider is licensed,
reputable and adheres to stringent safety protocols.
As rogue Internet pharmacies have been known to
hijack accreditation logos and place them on their
website,21 authenticities were veriﬁed if the seal had a
hyperlink that led the user to a veriﬁcation Web page.
We developed a survey instrument to evaluate the
quality of the e-pharmacies using items from the
DARTS (Date, Author, References, Type and Sponsor)
tool22—a tool for assessing the quality of online medi-
cine information and requirements outlined in the VIPP19
and the PharmacyChecker veriﬁcation programme.23
Items from DISCERN,24a checklist to help users of con-
sumer health information judge the quality of written in-
formation (e.g. Did the site describe risks of treatment?),
and the Health on the Net Foundation25 standards for eval-
uating the credibility of the sources (e.g. transparency—
was there a contact email address?) were also incorpo-
rated. The readability of the informationwas not assessed.
Evaluation of isotretinoin Pregnancy Prevention
Programme speciﬁc criteria. The content coverage
of the information speciﬁc to isotretinoin and preg-
nancy was assessed for accuracy and completeness
using 14 items derived from PPPs approved by the
Food and Drug Administration (iPLEDGE) and
Medicines and Healthcare Products Regulatory Agency
(MHRA) for dispensing isotretinoin to patients at risk of
pregnancy.2,3 Two of the authors independently (BML,
BW) reviewed and evaluated each of the 50 websites to
determine whether each criterion was ‘fully met’, ‘par-
tially met’ or ‘not met’ (i.e. provided no information).
Information was classiﬁed as ‘poor’ quality if the site
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did not mention that isotretinoin may cause severe birth
defects or did not mention that it should not be taken in
pregnancy or planning or at risk of a pregnancy.
Purchasing process
Within funds available for the research, a purchasing
request was submitted to the ﬁrst eight illegitimate
e-pharmacies (within the list of 50 surveyed), which
reported selling Accutane in 20mg capsules, did not
require a prescription, did not require the consumer to
register as a member and each had a different payment
IP addresses. A specially set-up prepaid credit card,
email account and an off-campus delivery address were
used for purchasing the samples, for protection of the
researcher and for reducing the risk of refusal by the
e-pharmacy.
Medications were assessed for price, conditions of
purchase [on the basis of European Council Directive
(2001/83/EC criteria)]26 and basic quality. Quality and
purity of the purchased medications were assessed by
one of the authors (DU) using high-performance liquid
chromatography with diode array detection. Prior to be
being sent for analysis, the seven purchased samples
and a ‘baseline standard control’, that is, known genuine
sample from a local hospital pharmacy, were labelled




In this study, 58% (n=29) of the websites originated
fromWestern Europe, 32% (n=16) fromNorth America
and 8% (n=4) from Eastern Europe. The origin of one
site could not be identiﬁed. The majority of the sites
(n=45, 90%) had a generic registration such as .com
(n = 38), .net (n= 4) or .org (n= 3) domain. The
remaining ﬁve websites had a country coded sufﬁx
(e.g. .uk, .us) domain. Almost half (n=21, 42%) of the
e-pharmacies had home and purchasing pages hosted
on servers in different countries. Five had ‘Canadian’
in the title of their Web page, but the IP address indi-
cated a domain location in various countries of Europe.
Eight sites displayed a pharmacy accreditation seal;
however, one of these was not authentic. Therefore,
seven (14%) were eligible to be classiﬁed as a ‘legiti-
mate’ e-pharmacies. The majority of the e-pharmacies
(n = 47, 94%) displayed some form of medication
quality assurance policy or statement such as ‘all generic
pills are FDA approved’, but 34 (68%) provided no indi-
cation as to where the medication was manufactured.
Fifteen (30%) stated the medication was manufactured
in India and one in the UK.
Table 1 provides an overview of risk reduction mea-
sures evident from reviewing each website. Displaying
an ‘authentic’ accreditation seal did not necessarily
mean there were procedures in place to minimise the
risk of harm for consumers purchasing this medication
online.
There were variations in prescription requirements
(Table 1). Thirty-three sites including one authenti-
cated site required no prescription at all. Some sites
had a ‘Prescription Policy’ as a link in diminutive font
size at the bottom of the Web page. These ‘Prescrip-
tion Policies’ included a disclaimer statement should
the consumer suffer any adverse effects from taking
the medication and shifted the responsibility for the
purchase from the supplier to the purchaser, evidenced
in the following statement:
…by placing the order on our site the user customer
conﬁrms …they have a valid prescription for the
drug they are ordering and their doctor has full
knowledge of this and all medications they are taking.
(Website 27—URL: Canada)
Table 1. Risk reduction procedures for purchasing isotretinoin displayed







Prescription requirements for isotretinoin
• None required 32 1
• ‘Prescription Policy’* 9 0
• Required from own healthcare
practitioner
0 6
• ‘May be required’ 2 0
Asked to complete medical questionnaire
• No 34 5
• Optional 7 1
• Compulsory 7 1
Restriction on quantity
• No limit stated 40 1
• As stated on prescription 0 3
• 1month supply 2 1
• 3months supply 1 2
Procedure for reporting adverse drug events
• Not mentioned 24 4
• Consumer contacts own
physician
18 3





*A hidden rider added to some websites, which stated that the consumer
was conﬁrming they ‘had a valid prescription for the drug’.
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Sixteen of the e-pharmacies asked the customer to
complete a medical questionnaire; however, this was
optional in half of these sites. The majority of sites
(82%), including one with a VIPP logo, did not stipu-
late a limit to the number of capsules that could be pur-
chased. Prices ranged from 50p to £3.67 per capsule.
Purchasing of single capsules was possible, but in
some cases, it was restricted to a minimum of 30.
Evaluation of pregnancy prevention information
Table 2 provides an evaluation of the content of the
information provided in relation to isotretinoin and
pregnancy. The Cronbach’s alpha for the PPP speciﬁc
criteria 14-item scale was 0.906 indicating high inter-
nal reliability. In the study, 78% of the sites provided
information of ‘poor’ quality as judged by whether
any of the ﬁrst three criteria shown in Table 2 were
not fully met. Only one site complied with all of the
requirements regarding information, by providing a link
to a PPP.
During the review process, statements provided on
the site were observed and recorded. Some of these were
misleading: with some openly encouraging online pur-
chasing of isotretinoin/Accutane/Roaccutane (Table 3).
Online purchasing
From the eight purchasing requests, seven resulted in
delivery of the product. One purchase was blocked
by the credit card company as the company was named
on their fraudulent blacklist. One of the sites required
the purchaser to complete a medical questionnaire,
for another, it was optional.
All seven purchased samples were received by mail
and franked in India. A custom declaration form
displaying minimal information was attached to each
package received. Figure 1 illustrates an example of
the packaging and presentation of the samples. None
of the samples were enclosed in a box or container.
Two samples were wrapped in bubble wrap, and one
was taped between two pieces of light cardboard. An
unexpected gift of four free tablets claiming to be Vi-
agra (we did not test the compound) was received with
one of the purchases (Figure 1).
None of the purchases were accompanied with a
manufacturer’s ‘patient information sheet’. However,
four of the samples did have a statement titled: ‘Warn-
ing to female patients’ written in minute text on the
blister pack: ‘This medication may cause severe birth
defects. You must not take this medicine if you are
pregnant or may likely to become pregnant during
treatment.’ Two of these four samples also had an
‘Avoid in Pregnancy’ logo on each of their blister
packs. The remaining three samples contained no ref-
erence or warning in relation to pregnancy.
Analysis of online purchases
Table 4 provides details and analysis of the seven pro-
cured drugs. The medication ordered from each site
was ‘Accutane’ 20mg, but a range of generic and
branded versions were received. The price per capsule
of the purchased drugs was approximately twice the
price of the same medication accessed locally in the
UK (£0.72). All products received were within the expi-
ration date. When the analyses of the purchased capsules
were compared against a quality control sample and the
Table 2. Evaluation of information provided on 50 e-pharmacy websites in relation to isotretinoin and pregnancy using Medicines and Healthcare products
Regulatory Agency4 and iPLEDGE5 Pregnancy Prevention Programme criteria










Isotretinoin may cause severe birth defects 24 (48) 1 (2) 23 (53) 2 (29)
Not to be taken in pregnancy 20 (40) 6 (12) 21 (49) 3 (43)
Not to be taken if planning a pregnancy 14 (28) 3 (6) 28 (65) 5 (71)
Speak to a doctor before taking 9 (18) 8 (16) 30 (70) 3 (43)
Two negative pregnancy tests prior to starting therapy 6 (12) 4 (8) 35 (81) 5 (71)
Use two forms of contraception 18 (36) 1 (2) 26 (60) 5 (71)
Avoid progesterone only pill 3 (6) 13 (26) 28 (65) 6 (86)
Certain medicines e.g. St John’s Wort may make contraceptives’ less effective 2 (4) 2 (4) 40 (93) 6 (86)
Monthly pregnancy test 7 (14) 9 (18) 28 (65) 6 (86)
Not getting pregnant for at least one month after stopping treatment 16 (32) 1 (2) 28 (65) 5 (71)
Informing doctor straight away if should become pregnant while taking isotretinoin 6 (12) 3 (6) 36 (84) 5 (71)
Increases chance of miscarriage 4 (8) 1 (2) 39 (91) 6 (86)
Don’t share medicine with anyone else, particularly females 1 (2) 13 (26) 30 (70) 6 (86)
Not donating blood for one month at least post stopping treatment 17 (34) 1 (2) 26 (60) 6 (86)
*One site provided a link to the Food and Drug Administration iPLEDGE programme and therefore met all criteria.
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British Pharmacopoeia27—standards for isotretinion
capsules—none of the samples failed the identiﬁcation,
related substance and assay test.
DISCUSSION
This study demonstrates that women of childbearing
age have the opportunity to purchase isotretinoin di-
rectly from websites that do not provide any form of
risk assessment, pregnancy prevention advice or ade-
quate warnings of the dangers associated with taking
this medication. A prescription is not required for pur-
chase at most sites. Women obtaining isotretinoin
from e-pharmacy sites may be at risk of becoming
pregnant and being exposed to a known and highly
potent teratogen. Even among accredited sites, only
one site provided, via a link, the full safety information
required by PPPs.
Table 3. Statements from websites selling isotretinoin
euromedicat study 415
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The advent of e-pharmacies has changed the dynam-
ics of the doctor/patient relationship, and the very na-
ture of e-pharmacies allows consumers to bypass the
safeguards provided by this relationship. PPPs man-
date that isotretinoin can only be prescribed by, or un-
der the supervision of, a specialist with expertise in the
use of systemic retinoids for the treatment of severe
forms of acne.2,3 The majority of the websites in this
study allowed customers to bypass these regulations,
allowing any person with access to the Internet to
self-prescribe. PPPs also stipulate that women must
take effective contraception and regular pregnancy
tests, but Internet purchase constitutes a loophole in
this risk minimisation measure as women are not re-
quired, and usually not even advised, to take these
measures. We recommend that PPPs are urgently re-
vised to take into account Internet access to isotreti-
noin. This issue was previously reported in 2005,14
and to date, there is no evidence of effective action
having been taken. Moreover, two of the seven sites
from which isotretinoin was purchased without pre-
scription are still (mid 2013) advertising that they are
selling isotretinoin, 18months after, the MHRA were
advised of this.
None of the purchased medicines were packaged
according to the European council directive 2001/83/
EC,25 which stipulates the sale of a medicinal product
without a proper container is in contravention to la-
belling controls S.85(4). Regulators such as the
MHRA state that the safe use of all medicines de-
pends on users reading the patient information sheet,
labelling and packaging carefully and accurately and
being able to assimilate and act on the information
presented. Four of the seven samples purchased for
this study had minimal pregnancy warning on the
blister pack, the other three none at all. None of the
drugs had a patient information leaﬂet or any instruc-
tions enclosed on how the medication should be
taken. Sites that required a prescription were prepared
to accept a fax or email, which is in contravention of
the recommendations of the General Pharmaceutical
Council20 about what constitutes a valid prescription.
According to the National Association of Boards of
Pharmacy,18 99% of the Internet drug companies they
review are not in compliance with state or federal
regulations.28
Governments have been slow to address the Internet
pharmacy problem. Because of the nature of the Inter-
net in having no geographical boundaries, and the lack
of harmonisation of regulatory policy at international
level, products can be bought from almost any part
of the world. From January 2013, the ‘new legislation
on falsiﬁed medicines’ for Europe aims to improve
the protection of public health by introducing new
harmonised, pan-European rules to ensure that medi-
cines are safe, particularly in being what they purport
to be, and that the trade in medicines is rigorously con-
trolled.29 Ironically perhaps, whereas much concern
centres on falsiﬁcation of Internet-purchased medicine,
we were able to verify the compound quality as the true,
but teratogenic, medication. Included in these European
Table 4. E-pharmacy and product characteristics and results of analysis of medications purchased from eight illegitimate sites
Sample 1 2 3 4 5 6 7
URL location of website Latvia Netherlands USA Spain Germany UK Russia
Source India India India India India India India
Product name Isotretinoin Acnomor Isotretinoin Treat-A Irotin Acnomor Irotin
Expiry date (months) 8 10 8 1 10 10 5
Price per capsule (£) 1.89 1.32 1.86 1.45 1.40 1.45 2.56
Acitretinoin <LOQ* <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ
Isotretinoin (mg) ±20 ±20 ±20 ±20 ±20 ±20 ±20
Tretinoin† (%) — <3 <2 — <1 <3 <1
MOB/POB‡ Present Present Present Present Present Present Present
*<LOQ (limit of quantiﬁcation) is not detectable.
†Tretinoin: a derivative of vitamin A.
‡MOB, methylparahydroxybenzoate (antifungal and antibacterial agents used as a preservative in pharmaceutical preparations). POB, propylparahydroxybenzoate
(an antimicrobial preservative).





received in blister 




Figure 1. An illustration of how one sample was received
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measures is the introduction of a common, European
Union-wide logo to identify legal online pharmacies. It
is envisaged that this will make it easier to distinguish
between legal and illegal e-pharmacies throughout the
European Union.29 However, logos and seals are not
enough. People must be educated about their meaning
and how to verify them (we found one false VIPP). The
presence of a logo may give false security to those who
purchase medicines online, and they may assume that
they are engaging in safe practices—we found that even
legitimate sites were not giving full safety information.
Our ﬁndings add additional evidence to substantiate
the need to engage in wide ranging international mea-
sures tominimise harm associated with online purchasing
of medications, including the potential harm of obtaining
medications without prescription, and obtaining medica-
tions without full safety information and associated risk
minimisation measures. This research shows that the
special case of pregnancy—women already pregnant
and women at risk of pregnancy should be speciﬁcally
addressed in these measures, involving as it does both
the woman and her unborn baby.
Whereas on the one hand, stricter control of online
pharmacies is required; on the one hand, PPPs must
recognise the potential for women to bypass the pre-
scriber, intentionally or unintentionally. This means,
for example, making young women aware by other
means (social media, magazines) of the potential
dangers of this form of acne medication, and also of
the potential dangers of Internet medication purchase,
and including these issues also in preconception care
for all women.30 General practitioners, dermatologists
and pharmacists need to reinforce these messages if they
believe their patients may consider online purchase.
This study goes further than previous reports regarding
isotretinoin by evaluating the safety information on the
websites, exploring the ease of the purchasing process
and verifying the quality and purity of the product pur-
chased online. However, a number of limitations of this
study should be recognised. The frequency with which
isotretinoin is purchased from the Internet was not
established nor the characteristics of women who pur-
chase or their reasons for doing so. Furthermore, our
results concern e-pharmacies accessible in the UK, and
different situations may prevail in other countries, for
example, in relation to e-pharmacy accessibility and
customs policies and practices. No attempt was made
to purchase samples from legitimate e-pharmacies.
The laboratory analysis of the purchased medications
was limited—the dissolution of the samples was not
tested, and the assay was carried out on only one
capsule per batch. However, some of these limitations
can be seen as avenues for future research.
CONCLUSIONS
Increasing awareness of Internet-based pharmacies
among health care providers is the ﬁrst step for health
care professionals to help limit the online purchasing
of isotretinoin and other potentially teratogenic drugs.
Health care providers should recognise that all consumers
of health care are susceptible and should educate clients
about the risks of purchasing medications over the Inter-
net without medical supervision. In addition, increased
awareness of the teratogenic potential of medications
needs to be part of preconception care and public health
interventions. This study evaluated the example of iso-
tretinoin, a highly teratogenic drug, but the implications
of Internet purchase relate also to drugs of unknown or
lesser teratogenicity. Regulation of drug safety in preg-
nancy by medicines regulatory agencies must take into
account the growing use of online pharmacies.
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